BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iacovelli R, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, Tortora G. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020;136:195-203. [PMID: 32712550 DOI: 10.1016/j.ejca.2020.06.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Bersanelli M, Rebuzzi SE, Roviello G, Catalano M, Brunelli M, Rizzo M. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma. Hum Vaccin Immunother 2023;19:2171672. [PMID: 36758960 DOI: 10.1080/21645515.2023.2171672] [Reference Citation Analysis]
2 Chen P, Bi F, Tan W, Jian L, Yu X. A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1127448] [Reference Citation Analysis]
3 Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 2023;20:133-57. [PMID: 36414800 DOI: 10.1038/s41585-022-00676-0] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer 2022;10. [PMID: 36549781 DOI: 10.1136/jitc-2022-005445] [Reference Citation Analysis]
5 Ito K, Kita Y, Kobayashi T. Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. Int J of Urology 2022. [DOI: 10.1111/iju.15101] [Reference Citation Analysis]
6 Shan L, Shao X, Gu L, Wu M, Lin P, Yu Z, Chen Q, Zhu D. Clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with sarcomatoid dedifferentiation: A PRISMA-compliant systematic review and meta-analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.922150] [Reference Citation Analysis]
7 xing Z, Chen Y, Cai G, Chen S. Clinical characteristic and survival analysis of distant metastatic sarcomatoid renal cell carcinoma: A study of 378 patients.. [DOI: 10.21203/rs.3.rs-1567322/v2] [Reference Citation Analysis]
8 Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current Oncology 2022;29:5475-5488. [DOI: 10.3390/curroncol29080433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vivekanandamoorthy N, Moghadam A, Hort A, Howle J. Malignant small bowel obstruction secondary to metastatic renal cell carcinoma with sarcomatoid transformation. Br J Hosp Med 2022;83:1-3. [DOI: 10.12968/hmed.2021.0626] [Reference Citation Analysis]
10 Patel HD, Man A, Koehne EL, Rac G, Aragao AP, Flanigan RC, Gorbonos A, Gupta GN, Woods ME, Picken MM, Quek ML. Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. Urologic Oncology: Seminars and Original Investigations 2022;40:347.e1-347.e8. [DOI: 10.1016/j.urolonc.2022.04.003] [Reference Citation Analysis]
11 Warli SM, Andy A, Mariedina CT, Nasution R, Kadar DD. A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient. RRU 2022;Volume 14:241-245. [DOI: 10.2147/rru.s370975] [Reference Citation Analysis]
12 Sawhney P, Suyanto S, Michael A, Pandha H. First-line therapy for metastatic renal cell carcinoma. Journal of Clinical Urology. [DOI: 10.1177/20514158221092949] [Reference Citation Analysis]
13 Xu Y, Huang Y, Zhang J. Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates. European Urology 2022. [DOI: 10.1016/j.eururo.2022.04.033] [Reference Citation Analysis]
14 Maughan BL. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022. Curr Oncol Rep 2022. [PMID: 35438388 DOI: 10.1007/s11912-022-01269-1] [Reference Citation Analysis]
15 Cetin B, Wabl CA, Gumusay O. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients. Curr Treat Options Oncol 2022. [PMID: 35316480 DOI: 10.1007/s11864-022-00966-0] [Reference Citation Analysis]
16 Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 dos Reis AFP, Simão D, Odeny T, Rodrigues C, Fontes-sousa M, Luz RD, Chowdry RP, Welsh SJ, Paller C, Barata PC. A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. KCA 2022. [DOI: 10.3233/kca-210012] [Reference Citation Analysis]
18 Pieretti AC, Ozambela M, Westerman ME, Nogueras-gonzalez GM, Segarra LA, Zacharias NM, Vaporciyan A, Hofstetter W, Huynh T, Aldousari S, Matin SF, Karam JA. Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.02.001] [Reference Citation Analysis]
19 Kim IH, Lee HJ. The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective. Biomedicines 2022;10:251. [PMID: 35203461 DOI: 10.3390/biomedicines10020251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Quhal F, Mori K, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Curr Opin Urol 2022;32:61-8. [PMID: 34720102 DOI: 10.1097/MOU.0000000000000940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World J Clin Oncol 2021; 12(11): 1037-1046 [PMID: 34909398 DOI: 10.5306/wjco.v12.i11.1037] [Reference Citation Analysis]
22 Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Maio MD. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy 2021. [PMID: 34806404 DOI: 10.2217/imt-2021-0157] [Reference Citation Analysis]
23 Anker J, Miller J, Taylor N, Kyprianou N, Tsao CK. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. Cells 2021;10:3231. [PMID: 34831452 DOI: 10.3390/cells10113231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Pesola G, Murianni V, Rebuzzi SE, Banna GL, Cerbone L, Catalano F, Borea R, Gandini A, Cremante M, Puglisi S, Trovato F, Fornarini G. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. Immunotherapy 2021;13:1379-86. [PMID: 34743545 DOI: 10.2217/imt-2021-0085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Jang A, Adler DM, Rauterkus GP, Bilen MA, Barata PC. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? Cancers (Basel) 2021;13:5065. [PMID: 34680214 DOI: 10.3390/cancers13205065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Vitale MG, Nasso C, Oltrecolli M, Baldessari C, Fanelli M, Dominici M, Sabbatini R. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. Expert Rev Anticancer Ther 2021;21:1183-92. [PMID: 34424125 DOI: 10.1080/14737140.2021.1971519] [Reference Citation Analysis]
27 Patel HV, Srivastava A, Srinivasan R, Singer EA. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma. Curr Opin Oncol 2021;33:212-20. [PMID: 33818540 DOI: 10.1097/CCO.0000000000000721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Choueiri TK, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open 2021;6:100101. [PMID: 33901870 DOI: 10.1016/j.esmoop.2021.100101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
29 Fu Y, Wang PP, He D, Zheng Y, Ding ZY. Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report. Thorac Cancer 2021;12:1234-9. [PMID: 33619875 DOI: 10.1111/1759-7714.13905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Halabi S, Armstrong AJ. Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset? Eur Urol 2021;79:663-4. [PMID: 33593655 DOI: 10.1016/j.eururo.2021.01.042] [Reference Citation Analysis]
31 Guida A, Sabbatini R, Gibellini L, De Biasi S, Cossarizza A, Porta C. Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for? Cancer Treat Rev 2021;94:102157. [PMID: 33607461 DOI: 10.1016/j.ctrv.2021.102157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Bersanelli M, Buti S, Rizzo M. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2021;21:401-12. [PMID: 33287612 DOI: 10.1080/14737140.2021.1861941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Park JJ, Kellezi O, Hamasha R, Ali A, Alva AS. Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience. Cancer Treat Res Commun 2020;25:100251. [PMID: 33310369 DOI: 10.1016/j.ctarc.2020.100251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
34 Zhi H, Feng M, Liu S, Na T, Zhang N, BiLiGe W. Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:591001. [PMID: 33134181 DOI: 10.3389/fonc.2020.591001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
36 Tucker MD, Rini BI. Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers (Basel) 2020;12:E2662. [PMID: 32961934 DOI: 10.3390/cancers12092662] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]